US 11286528
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted A61KA61K2039/6031A61K2039/6056
Quick answer
US patent 11286528 (Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy) held by BIOVERATIV THERAPEUTICS INC. expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BIOVERATIV THERAPEUTICS INC.
- Grant date
- Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/6031, A61K2039/6056, A61K38/21, A61K38/37